UCL Discovery
UCL home » Library Services » Electronic resources » UCL Discovery

The ASAS-OMERACT core domain set for axial spondyloarthritis

Navarro-Compán, V; Boel, A; Boonen, A; Mease, P; Landewé, R; Kiltz, U; Dougados, M; ... van der Heijde, D; + view all (2021) The ASAS-OMERACT core domain set for axial spondyloarthritis. Seminars in Arthritis and Rheumatism , 51 (6) pp. 1342-1349. 10.1016/j.semarthrit.2021.07.021. Green open access

[thumbnail of Machado_Main document.pdf]
Preview
Text
Machado_Main document.pdf - Accepted Version

Download (464kB) | Preview

Abstract

BACKGROUND: The current core outcome set for ankylosing spondylitis (AS) has had only minor adaptations since its development 20 years ago. Considering the significant advances in this field during the preceding decades, an update of this core set is necessary. OBJECTIVE: To update the ASAS-OMERACT core outcome set for AS into the ASAS-OMERACT core outcome set for axial spondyloarthritis (axSpA). METHODS: Following OMERACT and COMET guidelines, an international working group representing key stakeholders (patients, rheumatologists, health professionals, pharmaceutical industry and drug regulatory agency representatives) defined the core domain set for axSpA. The development process consisted of: i) Identifying candidate domains using a systematic literature review and qualitative studies; ii) Selection of the most relevant domains for different stakeholders through a 3-round Delphi survey involving axSpA patients and axSpA experts; iii) Consensus and voting by ASAS; iv) Endorsement by OMERACT. Two scenarios are considered based on the type of therapy investigated in the trial: symptom modifying therapies and disease modifying therapies. RESULTS: The updated core outcome set for axSpA includes 7 mandatory domains for all trials (disease activity, pain, morning stiffness, fatigue, physical function, overall functioning and health, and adverse events including death). There are 3 additional domains (extra-musculoskeletal manifestations, peripheral manifestations and structural damage) that are mandatory for disease modifying therapies and important but optional for symptom modifying therapies. Finally, 3 other domains (spinal mobility, sleep, and work and employment) are defined as important but optional domains for all trials. CONCLUSION: The ASAS-OMERACT core domain set for AS has been updated into the ASAS-OMERACT core domain set for axSpA. The next step is the selection of instruments for each domain.

Type: Article
Title: The ASAS-OMERACT core domain set for axial spondyloarthritis
Location: United States
Open access status: An open access version is available from UCL Discovery
DOI: 10.1016/j.semarthrit.2021.07.021
Publisher version: https://doi.org/10.1016/j.semarthrit.2021.07.021
Language: English
Additional information: This version is the author accepted manuscript. For information on re-use, please refer to the publisher’s terms and conditions.
Keywords: ASAS, Ankylosing spondylitis, Axial spondyloarthritis, Core outcome set, Domain, OMERACT, Outcome
UCL classification: UCL
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences > UCL Queen Square Institute of Neurology
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences > UCL Queen Square Institute of Neurology > Department of Neuromuscular Diseases
URI: https://discovery.ucl.ac.uk/id/eprint/10135451
Downloads since deposit
258Downloads
Download activity - last month
Download activity - last 12 months
Downloads by country - last 12 months

Archive Staff Only

View Item View Item